# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATIONDECISION SUMMARYASSAY AND INSTRUMENT

I Background Information:

A 510(k) Number K193490   
B Applicant First Light Diagnostics, Inc.   
C Proprietary and Established Names SensiTox C. difficile Toxin Test

D Regulatory Information

<table><tr><td rowspan=1 colspan=1>ProductCode(s)</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>RegulationSection</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>LLH</td><td rowspan=1 colspan=1>Class I</td><td rowspan=1 colspan=1>21 CFR 866.2660 -MicroorganismDifferentiation AndIdentification Device</td><td rowspan=1 colspan=1>MI - Microbiology</td></tr></table>

II Submission/Device Overview:

A Purpose for Submission: To obtain a substantial equivalence determination for the SensiTox C. difficile Toxin Test.   
B Measurand: Clostridioides (Clostridium) difficile toxins A and B   
C Type of Test: Automated qualitative immunoassay

# III Intended Use/Indications for Use:

A Intended Use(s): See Indications for Use below.   
B Indication(s) for Use: The SensiTox C. difficile Toxin Test in an immunofluorescence assay intended for the qualitative detection of Clostridioides difficile toxins A and/or B in human stool specimens. The test is intended as an aid in the diagnosis of C. difficile infection (CDI) in patients exhibiting symptoms of CDI. Negative results do not preclude toxigenic C. difficile infection. The SensiTox $C$ . difficile Toxin Test should not be used as the sole basis for treatment or other management decisions. The test can only be used with the MultiPath platform.   
C Special Conditions for Use Statement(s): Rx - For Prescription Use Only   
D Special Instrument Requirements: MultiPath Analyzer

# IV Device/System Characteristics:

# A Device Description:

The SensiTox C. difficile Toxin Test is a cartridge-based immunoassay intended to detect $C .$ . difficile toxin A and/or toxin B in stool samples from patients suspected of $C .$ . difficile infection (CDI). Each single-use test cartridge contains the lyophilized reagents required to perform three measurements each for C. difficile toxin A and toxin B: Total Signal Measurement, Neutralization Measurement, and Positive Control Measurement. The test kit also includes the following components used to prepare specimens for testing: C. difficile Stool Specimen Diluent, C. difficile Protease Inhibitor reagent, and Spin Columns for stool specimen manual filtration.

The assay is performed on the MultiPath Analyzer, which is an automated benchtop laboratory instrument intended for use by trained laboratory technicians. The Analyzer includes the following functionality: a barcode scanner for test-specific and specimen-specific information, a pneumatic system that drives fluidics within the test cartridge, a magnetic station that deposits magnetically-tagged fluorescent targeted molecules onto the cartridge imaging surface, an optical system to detect deposited fluorescent particles, and automated software to analyze the test measurement and interpret the results based on predefined signal measurement thresholds for Toxin A and Toxin B total signals and neutralization measurements. The Analyzer uses a touch screen display User Interface to convey test information, status, instructions and user input. Up to five cartridges can be loaded onto the Analyzer at one time.

# B Principle of Operation:

The SensiTox C. difficile Toxin Test uses separate monoclonal antibodies that are conjugated to magnetic particles or fluorescent particles to capture and detect antigen, respectively. Labeled antibody-antigen complexes are deposited onto an imaging surface, and the MultiPath Analyzer uses digital imaging to automatically detect and interpret the assay signal.

# C Instrument Description Information:

<table><tr><td rowspan=1 colspan=1>Modes of Operation</td><td rowspan=1 colspan=1>Yes</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>Does the applicant&#x27;s device contain the ability to transmit data to a computer,webserver, or mobile device?</td><td rowspan=1 colspan=1>X</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Does the applicant&#x27;s device transmit data to a computer, webserver, or mobile deviceusing wireless transmission?</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>X</td></tr><tr><td rowspan=1 colspan=3>Software</td></tr><tr><td rowspan=1 colspan=1>FDA has reviewed applicant&#x27;s Hazard Analysis and software development processesfor this line of product types.</td><td rowspan=1 colspan=1>X</td><td rowspan=1 colspan=1></td></tr></table>

1. Instrument Name:

MultiPath Analyzer

2. Specimen Identification:

The MultiPath Analyzer scans the two barcodes on the Cartridge: a manufacturer-provided barcode that identifies the test to be performed, along with the reagent lot information and a laboratory-generated barcode affixed by the user to identify the patient specimen.

3. Specimen Sampling and Handling:

Stool specimens are manually diluted into corresponding Specimen Diluent tubes immediately before testing. The diluted specimen is added to a Spin Column tube labeled with the specimen identifier and centrifuged. The eluate is transferred to the Specimen Well of the Cartridge which is then placed in a multi-Cartridge rack that is loaded into the MultiPath Analyzer.

4. Calibration:

The MultiPath Analyzer is calibrated by the manufacturer. Yearly maintenance is performed by qualified service personnel to clean, calibrate, test and verify the functionality of the device.

5. Quality Control:

Internal Controls The C. difficile Cartridge contains two Internal Positive Control wells, one specific for Toxin A (5x LoD) and one specific for Toxin B (10x LoD), that ensure the sample matrix does not negatively impact the performance of the test. An invalid result will be reported if the Internal Positive Control generates a signal below its defined threshold.

# External Controls

The SensiTox C. difficile External Controls Kit containing positive and negative controls is provided separately. The positive control consists of lyophilized purified Toxin A and Toxin B in a buffered solution and the negative control consists of buffered solution. The External Controls are used periodically to verify performance of the reagents and the MultiPath Analyzer. It is recommended that External Controls be tested at least once every 30 days, when a new reagent lot is received in the laboratory, and when the MultiPath Analyzer undergoes installation, repair or maintenance procedures. External Controls should be tested in accordance with all institutional, local, state, federal, and accrediting agency guidelines.

# V Substantial Equivalence Information:

A Predicate Device Name(s): Immunocard Toxins A & B, Model 712050   
B Predicate 510(k) Number(s): K041003

C Comparison with Predicate(s):

<table><tr><td colspan="1" rowspan="1">Device &amp; PredicateDevice(s):</td><td colspan="1" rowspan="1">DEVICEK193490</td><td colspan="1" rowspan="1">PREDICATEK041003</td></tr><tr><td colspan="1" rowspan="1">Device Trade Name</td><td colspan="1" rowspan="1">SensiTox C. difficileToxin Test</td><td colspan="1" rowspan="1">ImmunoCard Toxins A&amp; B</td></tr><tr><td colspan="3" rowspan="1">General Device Characteristic Similarities</td></tr><tr><td colspan="1" rowspan="1">Intended Use/IndicationsFor Use</td><td colspan="1" rowspan="1">The SensiTox C.difficile Toxin Test is animmunofluorescenceassay intended for thequalitative detection ofClostridioides difficiletoxins A and/or B inhuman stool specimens.The test is intended asan aid in the diagnosisof C. difficile infection(CDI) in patientsexhibiting symptoms ofCDI. Negative resultsdo not precludetoxigenic C. difficileinfection. The SensiToxC. difficile Toxin Testshould not be used asthe sole basis for</td><td colspan="1" rowspan="1">ImmunoCard Toxins A&amp; B is a rapid,qualitative, horizontal-flow enzymeimmunoassay (EIA) fordetecting Clostridiumdifficile toxins A and Bin human stool. Thisassay is used as an aidin the diagnosis of C.difficile-associateddisease.</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">treatment or othermanagement decisions.The test can only beused with the MultiPathplatform.</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Analyte</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">C. difficile toxins A andB</td></tr><tr><td colspan="1" rowspan="1">Specimen type</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Human Stool</td></tr><tr><td colspan="1" rowspan="1">Interpretation</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Qualitative</td></tr><tr><td colspan="3" rowspan="1">General Device Characteristic Differences</td></tr><tr><td colspan="1" rowspan="1">Test format</td><td colspan="1" rowspan="1">Cartridge-basedimmunofluorescenceimmunoassay withautomatedinterpretation</td><td colspan="1" rowspan="1">Lateral flow enzymeimmunoassay withvisual interpretation</td></tr><tr><td colspan="1" rowspan="1">Antibodies</td><td colspan="1" rowspan="1">Capture and Detection:Mouse monoclonal anti-toxin A and Bantibodies</td><td colspan="1" rowspan="1">Capture:Monoclonal anti-toxinA and goat polyclonalanti-toxin B antibodiesDetection:Goat polyclonal anti-toxin A and Bantibodies</td></tr><tr><td colspan="1" rowspan="1">Automated</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">Instrument</td><td colspan="1" rowspan="1">Multipath Analyzer</td><td colspan="1" rowspan="1">None</td></tr></table>

# VI Standards/Guidance Documents Referenced:

IEC 60601-1-2:2014 General Requirements for Basic Safety and Essential performance – Collateral Standard: Electromagnetic Disturbances – Requirements and Tests ANSI/AAMI/IEC 62304:2006 & A1:2016 (Consolidated Text): Medical Device Software - Software Life Cycle Processes ISO 14971 (3rd Edition): Medical devices — Application of risk management to medical devices • ISO/IEC 24778:2008: Information technology — Automatic identification and data capture techniques — Aztec Code bar code symbology specification

# VII Performance Characteristics (if/when applicable):

A Analytical Performance:

1. Precision/Reproducibility:

The reproducibility of the SensiTox $C .$ . difficile Toxin Test was evaluated at three sites over five days by two operators each day. The sample panels consisted of Stool Specimen Diluent aliquots spiked with both Toxins A and B at the following concentrations: low positive ( $_ { 1 - 2 \tt X }$ LoD), moderate positive (2-4x LoD), high positive (5-8x LoD), and negative (unspiked). The panels were randomized and masked and then distributed to each site. Prior to testing, each operator mixed the designated sample with pooled stool matrix that was prescreened and known to be negative for C. difficile Toxins A and B. The samples were processed according to the labelled test procedure and tested with the SensiTox C. difficile Toxin Test in triplicate for a total of 90 observations per panel member. The qualitative test results for detecting Toxin A (Table 1), Toxin B (Table 2) and each panel member (i.e., detection of Toxin A or B, Table 3. Reproducibility – Table 3) are summarized below.

Overall, 16/360 $( 4 . 4 \% )$ samples initially produced invalid results in the study. All samples were valid upon retest following labeled instructions. All high positive panel members produced the expected positive results for both toxin A and B (90/90, $100 \%$ ). For the moderate positive panel members, one sample produced false negative results for both toxin A and B at one site (89/90, $9 8 . 9 \% $ . Also, one negative sample at the same site produced false positive results for both toxin A and B $( 8 9 / 9 0 , 9 8 . 9 \% )$ . For the low positive panel members, one sample produced a false negative result for toxin A at one site $( 8 9 / 9 0 , 9 8 . 9 \% )$ , and all sites produced the expected positive result for toxin B $( 9 0 / 9 0 , 1 0 0 \% )$ .

Table 1. Reproducibility – Toxin A   

<table><tr><td rowspan=2 colspan=1>Toxin APanel</td><td rowspan=1 colspan=2>Site 1</td><td rowspan=1 colspan=2>Site 2</td><td rowspan=1 colspan=2>Site 3</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>#</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>#</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>#</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>#</td><td rowspan=1 colspan=1>%</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>29/30</td><td rowspan=1 colspan=1>96.7%</td><td rowspan=1 colspan=1>89/90</td><td rowspan=1 colspan=1>98.9%</td></tr><tr><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>29/30</td><td rowspan=1 colspan=1>96.7%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>89/90</td><td rowspan=1 colspan=1>98.9%</td></tr><tr><td rowspan=1 colspan=1>Moderate</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>29/30</td><td rowspan=1 colspan=1>96.7%</td><td rowspan=1 colspan=1>89/90</td><td rowspan=1 colspan=1>98.9%</td></tr><tr><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>90/90</td><td rowspan=1 colspan=1>100%</td></tr></table>

Table 2. Reproducibility – Toxin B   

<table><tr><td rowspan=2 colspan=1>Toxin BPanel</td><td rowspan=1 colspan=2>Site 1</td><td rowspan=1 colspan=2>Site 2</td><td rowspan=1 colspan=2>Site 3</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>#</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>#</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>#</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>#</td><td rowspan=1 colspan=1>%</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>29/30</td><td rowspan=1 colspan=1>96.7%</td><td rowspan=1 colspan=1>89/90</td><td rowspan=1 colspan=1>98.9%</td></tr><tr><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>90/90</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>Moderate</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>29/30</td><td rowspan=1 colspan=1>96.7%</td><td rowspan=1 colspan=1>89/90</td><td rowspan=1 colspan=1>98.9%</td></tr><tr><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>90/90</td><td rowspan=1 colspan=1>100%</td></tr></table>

Table 3. Reproducibility – Per Panel Member   

<table><tr><td rowspan=2 colspan=1>Toxin BPanel</td><td rowspan=1 colspan=2>Site 1</td><td rowspan=1 colspan=2>Site 2</td><td rowspan=1 colspan=2>Site 3</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>#</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>#</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>#</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>#</td><td rowspan=1 colspan=1>%</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>29/30</td><td rowspan=1 colspan=1>96.7%</td><td rowspan=1 colspan=1>89/90</td><td rowspan=1 colspan=1>98.9%</td></tr><tr><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>29/30</td><td rowspan=1 colspan=1>96.7%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>89/90</td><td rowspan=1 colspan=1>98.9%</td></tr><tr><td rowspan=1 colspan=1>Moderate</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>29/30</td><td rowspan=1 colspan=1>96.7%</td><td rowspan=1 colspan=1>89/90</td><td rowspan=1 colspan=1>98.9%</td></tr><tr><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>90/90</td><td rowspan=1 colspan=1>100%</td></tr></table>

2. Linearity:

Not applicable

# Interfering substances

Endogenous and exogenous substances commonly found in stool were evaluated for their potential effect on the performance of the SensiTox $C .$ . difficile Toxin Test. Negative pooled stool and contrived positive pooled stool containing $1 5 ~ \mathrm { n g / m L }$ of Toxin A (4x LoD) and 300 $\boldsymbol { \mathrm { p g / m L } }$ of Toxin B (6x LoD) were tested unspiked (positive and negative control) as well as spiked with the potential interferents shown in Table 4 and tested in triplicate.

All negative samples produced the expected negative results in the presence of each substance. One initial invalid result was observed in the presence of Metronidazole at 40 $\mathrm { m g / m L }$ (1/115, $0 . 9 \%$ initial invalid rate); however, the sample produced the valid expected result upon repeat testing ( $0 \%$ final invalid rate). Out of six sample replicates tested with Vancomycin at $5 0 ~ \mathrm { m g / m L }$ , one false negative Toxin A result and one false negative Toxin B result were observed. No assay interference was observed in the presence of Vancomycin at $4 0 \mathrm { m g / m L }$ or in the presence of the other substances at the concentrations tested.

Table 4. Potential Interfering Substances   

<table><tr><td rowspan=1 colspan=1>Potential Interfering Substance</td><td rowspan=1 colspan=1>Concentration Tested</td></tr><tr><td rowspan=1 colspan=1>Nystatin</td><td rowspan=1 colspan=1>500 U/mL (5% w/v)</td></tr><tr><td rowspan=1 colspan=1>Barium Sulphate</td><td rowspan=1 colspan=1>50 mg/mL (5% w/v)</td></tr><tr><td rowspan=1 colspan=1>Hydrocortisone</td><td rowspan=1 colspan=1>0.5 mg/mL (5% w/v)</td></tr><tr><td rowspan=1 colspan=1>Phenylephrine (Preparation H)</td><td rowspan=1 colspan=1>0.1 mg/mL (5% w/v)</td></tr><tr><td rowspan=1 colspan=1>Calcium Carbonate (Tums)</td><td rowspan=1 colspan=1>10.4 mg/mL (5% w/v)</td></tr><tr><td rowspan=1 colspan=1>Aluminum Hydroxide / MagnesiumHydroxide (Sunmark antacid)</td><td rowspan=1 colspan=1>1 mg/mL (5% v/v)</td></tr><tr><td rowspan=1 colspan=1>Loperamide Hydrochloride (Imodium)</td><td rowspan=1 colspan=1>3.3 μg/mL (5% v/v)</td></tr><tr><td rowspan=1 colspan=1>Bismuth Subsalicylate (Pepto Bismol)</td><td rowspan=1 colspan=1>0.2 mg/mL (5% v/v)</td></tr><tr><td rowspan=1 colspan=1>Sennosides (Senokot)</td><td rowspan=1 colspan=1>0.6 mg/mL (5% w/v)</td></tr><tr><td rowspan=1 colspan=1>Metronidazole in DMSO</td><td rowspan=1 colspan=1>50 mg/mL (5% w/v)</td></tr><tr><td rowspan=1 colspan=1>Vancomycin</td><td rowspan=1 colspan=1>40 mg/mL (4% w/v)</td></tr><tr><td rowspan=1 colspan=1>Mucin</td><td rowspan=1 colspan=1>50 mg/mL (5% w/v)</td></tr><tr><td rowspan=1 colspan=1>DMSO</td><td rowspan=1 colspan=1>10% v/v</td></tr><tr><td rowspan=1 colspan=1>Whole Blood</td><td rowspan=1 colspan=1>40% v/v</td></tr></table>

# Analytical Specificity

The analytical specificity of the SensiTox $C .$ difficile Toxin Test was evaluated by testing a panel of microorganisms commonly found in stool samples (Table 5). Cultured organisms were spiked into negative pooled stool or spiked into contrived positive stool containing 15 $\mathrm { n g / m L }$ Toxin A $\left( 4 \mathbf { x } \ L \mathbf { o } \mathbf { D } \right)$ and $3 0 0 \mathrm { p g / m L }$ Toxin B (6x LoD). Bacteria and yeast were tested at $1 \mathrm { x } 1 0 ^ { 6 } \mathrm { C F U / m L }$ and viruses were tested at $1 \mathrm { x } 1 0 ^ { 5 } \mathrm { P F U / m L }$ , except for Norovirus $( 7 \mathrm { x } 1 0 ^ { 4 }$ $\mathrm { P F U / m L }$ ) and Echovirus $( 4 . 1 \mathrm { x } 1 0 ^ { 4 } \mathrm { P F U / m L } )$ ). All microorganisms were tested in triplicate with the SensiTox $C .$ . difficile Toxin Test. No false positive results were observed. Initial invalid results were obtained for four samples (4/135, $3 . 0 \%$ initial invalid rate), and all samples produced the expected valid result upon repeat ( $0 \%$ final invalid rate).

Table 5. Potential Interfering Microbes   

<table><tr><td>Microorganism</td><td>Microorganism</td></tr><tr><td>Adenovirus</td><td>Enterovirus</td></tr><tr><td colspan="1" rowspan="1">Aeromonas hydrophila</td><td colspan="1" rowspan="1">Escherichia coli</td></tr><tr><td colspan="1" rowspan="1">Bacillus cereus</td><td colspan="1" rowspan="1">Escherichia coli sero:0157</td></tr><tr><td colspan="1" rowspan="1">Bacillus subtilis</td><td colspan="1" rowspan="1">Escherichia coli type 026:H4</td></tr><tr><td colspan="1" rowspan="1">Bacteroides fragilis</td><td colspan="1" rowspan="1">Helicobacter pylori</td></tr><tr><td colspan="1" rowspan="1">Campylobacter jejuni</td><td colspan="1" rowspan="1">Klebsiella oxytoca</td></tr><tr><td colspan="1" rowspan="1">Campylobacter coli</td><td colspan="1" rowspan="1">Norovirus</td></tr><tr><td colspan="1" rowspan="1">Candida albicans</td><td colspan="1" rowspan="1">Peptostreptococcus anaerobius</td></tr><tr><td colspan="1" rowspan="1">Clostridium difficile (non-toxigenic)</td><td colspan="1" rowspan="1">Proteus vulgaris</td></tr><tr><td colspan="1" rowspan="1">Clostridium haemolyticum</td><td colspan="1" rowspan="1">Pseudomonas aeruginosa</td></tr><tr><td colspan="1" rowspan="1">Clostridium novyi</td><td colspan="1" rowspan="1">Rotavirus</td></tr><tr><td colspan="1" rowspan="1">Clostridium perfringens</td><td colspan="1" rowspan="1">Salmonella enterica (typhimurium)</td></tr><tr><td colspan="1" rowspan="1">Clostridium septicum</td><td colspan="1" rowspan="1">Serratia liquefaciens</td></tr><tr><td colspan="1" rowspan="1">Clostridium sordelliil</td><td colspan="1" rowspan="1">Shigella dysenteriae</td></tr><tr><td colspan="1" rowspan="1">Clostridium sporogenes</td><td colspan="1" rowspan="1">Shigella flexneri</td></tr><tr><td colspan="1" rowspan="1">Coxsackie virus</td><td colspan="1" rowspan="1">Shigella sonnei</td></tr><tr><td colspan="1" rowspan="1">Cytomegalovirus</td><td colspan="1" rowspan="1">Staphylococcus aureus</td></tr><tr><td colspan="1" rowspan="1">Echovirus</td><td colspan="1" rowspan="1">Staphylococcus epidermidis</td></tr><tr><td colspan="1" rowspan="1">Enterobacter aerogenes</td><td colspan="1" rowspan="1">Vibrio cholera</td></tr><tr><td colspan="1" rowspan="1">Enterobacter cloacae</td><td colspan="1" rowspan="1">Vibrio parahaemolyticus</td></tr><tr><td colspan="1" rowspan="1">Enterococcus faecalis</td><td colspan="1" rowspan="1"></td></tr></table>

1 The potential for purified Clostridium sordellii toxin to cross-react was not evaluated. It is unknown if $C .$ . sordellii toxin concentration in the $1 0 ^ { 6 } \mathrm { C F U / m L }$ preparation that was tested falls below the limit of detection for the SensiTox $C .$ . difficile Toxin Test.

# Microbial Interference

Microbial interference was evaluated for the SensiTox $C .$ . difficile Toxin Test by using the same panel of microorganisms from in the analytical specificity study (Table 5) spiked into contrived positive stool containing $1 5 ~ \mathrm { n g / m L }$ Toxin A (4x LoD) and $3 0 0 \mathrm { p g / m L }$ Toxin B (6x LoD). Toxins A and B were detected in all samples indicating lack of interference. However, one initial invalid result was observed (1/135, $0 . 7 \%$ initial invalid rate), and the sample produced the expected valid result upon retest per the study protocol and assay instructions ( $0 \%$ final invalid rate).

# Hook Effect

A study was conducted with the SensiTox $C .$ . difficile Toxin Test to determine if high concentrations of target $C .$ difficile toxins interfere with the test result (hook effect). Diluted toxins (Toxin A dilutions from $5 0 ~ \mu \mathrm { g / m L } - 2 . 5 ~ \mathrm { n g / m L }$ , Toxin B dilutions from $1 . 3 ~ \mu \mathrm { g / m L } -$ $6 6 ~ \mathrm { p g / m L }$ ) were spiked into pooled negative stool and three replicates per dilution were tested with the SensiTox C. difficile Toxin Test. No false negative results were observed for either toxin at any concentration tested.

4. Assay Reportable Range: Not applicable

# Quality Control

The SensiTox C. difficile Toxin Test uses internal positive controls (individual wells specific to each toxin and contained within the test cartridge) as well as external positive and negative controls. Quality control procedures monitor the accuracy and precision of the analytical process. It is recommended that External Controls be tested at least once every 30 days, when a new reagent lot is received in the laboratory, and when the MultiPath Analyzer undergoes installation, repair or maintenance procedures. External controls are required but not provided with the SensiTox C. difficile Toxin Test.

A minimum of one positive and one negative external control were used each day prior to testing clinical specimens or performing analytical studies. Controls were processed in the same manner as clinical specimens and results interpreted in accordance with the SensiTox C. difficile Toxin Test software assay parameters. To pass, a positive control must detect both Toxins A and B while the negative control must generate a negative result for both, according to the instructions for use of the external control kit. During the clinical study, a total of 343 external controls were run (169 positive and 174 negative controls). Of the 343 controls tested, 10 generated invalid results ( $2 . 9 \%$ invalid rate). Of the 333 valid QC results, two were QC failures (i.e., incorrect result). Per the study protocol, when this occurred another control was tested and passed which made the clinical specimen data acceptable for analysis on those days.

# MultiPath Analyzer

Additional assay and instrument parameters are monitored during a test run on the MultiPath Analyzer. These include sample input errors, instrument cartridge processing errors, and instrument system messages.

# Specimen Stability

A study was conducted to evaluate the stability of stool samples that have been stored refrigerated at $2 - 8 \ { } ^ { \circ } { \mathrm { C } }$ for analysis with the SensiTox C. difficile Toxin Test. Seven individual stool samples and one pool of two stool samples were collected and confirmed negative for $C .$ . difficile A and B toxins with the SensiTox $C .$ difficile Toxin Test. Sample aliquots were spiked with each target toxin individually at $1 5 ~ \mathrm { n g / m L }$ (4x LoD) for Toxin A and $2 5 0 ~ \mathrm { p g / m L }$ (5x LoD) for Toxin B. The samples were stored refrigerated and a minimum of three replicates each were tested with the SensiTox $C .$ . difficile Toxin Test at different time points. Spiked samples were tested after 0, 24, 48, 72, 96, and 100 hours of storage, and unspiked negative samples were tested after 0, 96, and 100 hours of storage.

Although there were trends of decreasing assay toxin signal average values and increasing neutralization ratio average values in spiked samples over time, the values were well within the cutoff threshold values to support a 72 hours stability claim when stored refrigerated at 2 $- 8 ^ { \circ } \mathrm { C }$ .

# 6. Detection Limit and Analytical Reactivity:

# Limit of Detection

The limit of detection (LoD) for Toxins A and B was determined by spiking known concentrations of purified Toxin A and B into negative pooled stool and testing with the

SensiTox $C .$ difficile Toxin Test. Concentrations ranging from 1.5 to $3 . 5 ~ \mathrm { n g / m L }$ for Toxin A and 30 to $1 0 0 ~ \mathrm { p g / m L }$ for Toxin B were tested using three reagent lots across two analyzers. Twenty replicates per analyte dilution and per reagent lot were tested for a total of 60 replicates per analyte concentration. The LoD for each toxin was defined as the lowest concentration that generated a Detected result $\ge 9 5 \%$ of the time. The LoD for Toxin A was $3 . 5 ~ \mathrm { n g / m L }$ and the LoD for Toxin B was $5 0 ~ \mathrm { p g / m L }$ .

# Analytical reactivity (Inclusivity)

A study was conducted to demonstrate reactivity of the SensiTox $C .$ . difficile Toxin Test with C. difficile A and B toxins sourced from a diverse collection of clinically relevant $C .$ . difficile strain ribotypes and toxinotypes (Table 6). Toxin A was purified from six ribotypes and tested at $1 5 ~ \mathrm { n g / m L }$ (4x LoD). Toxin B was purified from eight ribotypes and tested at 300 $\boldsymbol { \mathrm { p g / m L } }$ (6x LoD). As a positive control, Toxins A and B were purified from the wildtype strain (ribotype 087), which was the standard toxin used throughout product development. All samples produced the expected positive result with the SensiTox $C .$ . difficile Toxin Test. One initial invalid result was observed in the study (1/49, $2 . 0 \%$ initial invalid rate), and this sample produced the valid expected result upon repeat testing ( $0 \%$ final invalid rate).

Table 6. C. difficile strain ribotypes source of purified toxin used in Inclusivity Study   

<table><tr><td rowspan=1 colspan=1>TargetToxin</td><td rowspan=1 colspan=1>C. difficileRibotype</td><td rowspan=1 colspan=1>C. difficileToxinotype</td><td rowspan=1 colspan=1>ClinicalIsolate</td></tr><tr><td rowspan=6 colspan=1>Toxin A</td><td rowspan=1 colspan=1>001</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>L1228</td></tr><tr><td rowspan=1 colspan=1>002</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>D2177</td></tr><tr><td rowspan=1 colspan=1>014</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>D1321</td></tr><tr><td rowspan=1 colspan=1>027</td><td rowspan=1 colspan=1>III</td><td rowspan=1 colspan=1>1412</td></tr><tr><td rowspan=1 colspan=1>078</td><td rowspan=1 colspan=1>V</td><td rowspan=1 colspan=1>312</td></tr><tr><td rowspan=1 colspan=1>106</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>B5343</td></tr><tr><td rowspan=8 colspan=1>Toxin B</td><td rowspan=1 colspan=1>001</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>L1228</td></tr><tr><td rowspan=1 colspan=1>002</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>D2177</td></tr><tr><td rowspan=1 colspan=1>014</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>D1321</td></tr><tr><td rowspan=1 colspan=1>017</td><td rowspan=1 colspan=1>VIII</td><td rowspan=1 colspan=1>NCTC 13569</td></tr><tr><td rowspan=1 colspan=1>027</td><td rowspan=1 colspan=1>III</td><td rowspan=1 colspan=1>1412</td></tr><tr><td rowspan=1 colspan=1>036</td><td rowspan=1 colspan=1>X</td><td rowspan=1 colspan=1>CCUG 20309</td></tr><tr><td rowspan=1 colspan=1>078</td><td rowspan=1 colspan=1>V</td><td rowspan=1 colspan=1>312</td></tr><tr><td rowspan=1 colspan=1>106</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>B5343</td></tr></table>

# 7. Assay Cut-Off:

Assay parameter thresholds were established based on the evaluation of negative stool specimens, contrived stool specimens spiked with C. difficile A and B toxins, and clinical specimens characterized by cellular cytotoxicity neutralization assay (CCNA) for $C .$ difficile toxins. This included approximately 200 spiked specimens, 500 initial CCNA specimens, and an additional 300 CCNA specimens for confirmation.

8. Accuracy (Instrument): Not applicable

A study was conducted to determine if carry-over contamination occurs within runs or between runs with the SensiTox C. difficile Toxin Test on the MultiPath Analyzer. The study used negative pooled stool samples and high positive samples contrived by spiking both Toxin A and B into negative stool at a concentration of $1 . 3 ~ \mu \mathrm { g / m L }$ (more than 370X LoD for Toxin A and 26,000X LoD for Toxin B). In total, 13 high positive and 13 negative samples were prepared in individual test cartridges and run on one MultiPath Analyzer using an alternating pattern within-run and between-run for a total of five runs. No evidence of carryover effect was observed as all negative samples in the study produced the expected Not Detected result for both toxins.

# B Comparison Studies:

1. Method Comparison with Predicate Device: Not applicable

2. Matrix Comparison: Not applicable

# C Clinical Studies:

# 1. Clinical Sensitivity:

The performance of the SensiTox $C .$ . difficile Toxin Test was evaluated in a prospective clinical study performed at three geographically diverse sites in the US. The study tested leftover, de-identified, unpreserved liquid or soft stool specimens sequentially collected from patients suspected of $C .$ . difficile infection. Stool specimens were stored up to 72 hours refrigerated at $2 - 8 \ { } ^ { \circ } { \mathrm { C } }$ prior to testing with the investigational device. Test performance was evaluated in comparison to the results of the cellular cytotoxicity neutralization assay which detects the presence of $C .$ . difficile toxin in fecal sample filtrates. Samples were stored and tested in accordance with the assay instructions and specifications.

Specimen inclusion and exclusion criteria were defined in the protocol. Specimens that met the study inclusion criteria and that did not meet any of the exclusion criteria were included in the analysis. Out of 1107 enrolled samples, 27 samples were excluded from the analysis due to sample processing or shipping errors and 20 samples were excluded due to storage outside of the sample stability timeframe. Results from a total of 1060 samples were available for analysis; 621 $( 5 9 \% )$ collected from females, 438 $( 4 1 \% )$ collected from males, and one collected from an individual whose gender was unknown. The age distribution is shown in Table 7.

Table 7. Age Distribution   

<table><tr><td colspan="1" rowspan="1">Age</td><td colspan="1" rowspan="1">n</td><td colspan="1" rowspan="1">%</td></tr><tr><td colspan="1" rowspan="1">2-21</td><td colspan="1" rowspan="1">40</td><td colspan="1" rowspan="1">3.8%</td></tr><tr><td colspan="1" rowspan="1">22-59</td><td colspan="1" rowspan="1">440</td><td colspan="1" rowspan="1">41.5%</td></tr><tr><td colspan="1" rowspan="1">&gt;60</td><td colspan="1" rowspan="1">580</td><td colspan="1" rowspan="1">54.7%</td></tr><tr><td colspan="1" rowspan="1">Total</td><td colspan="1" rowspan="1">1060</td><td colspan="1" rowspan="1">100%</td></tr></table>

Of the 1060 samples, 14 samples $( 1 . 3 \% )$ required repeat testing with the SensiTox C. difficile Toxin Test due to initial invalid results, per the protocol. However, samples were not retested because they were either unavailable or exceeded the 72-hour sample stability timeframe. The remaining 1046 samples with valid results were included in the performance analysis.

The performance of the SensiTox $C .$ difficile Toxin Test compared to the cellular cytotoxicity neutralization assay is shown in Table 8.

Table 8. Performance of the SensiTox C. difficile Toxin Test   

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=3>Cellular Cytotoxicity Neutralization Assay</td></tr><tr><td rowspan=1 colspan=1>Detected</td><td rowspan=1 colspan=1>Not Detected</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>SensiToxC. difficile ToxinTest</td><td rowspan=1 colspan=1>Detected</td><td rowspan=1 colspan=1>87</td><td rowspan=1 colspan=1>41</td><td rowspan=1 colspan=1>128</td></tr><tr><td rowspan=1 colspan=1>Not Detected</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>909</td><td rowspan=1 colspan=1>918</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>96</td><td rowspan=1 colspan=1>950</td><td rowspan=1 colspan=1>1046</td></tr><tr><td rowspan=1 colspan=2>Sensitivity (95% CI)</td><td rowspan=1 colspan=3>90.6% (83.1 - 95.0%)</td></tr><tr><td rowspan=1 colspan=2>Specificity (95% CI)</td><td rowspan=1 colspan=3>95.7% (94.296.8%)</td></tr><tr><td rowspan=1 colspan=2>Positive Predictive Value (95% CI)</td><td rowspan=1 colspan=3>68.0% (59.5 - 75.4%)</td></tr><tr><td rowspan=1 colspan=2>Negative Predictive Value (95% CI)</td><td rowspan=1 colspan=3>99.0% (98.1  99.5%)</td></tr></table>

2. Clinical Specificity: See Section VII.C.1.

3. Other Clinical Supportive Data (When 1. and 2. Are Not Applicable): Not applicable

# D Clinical Cut-Off:

Not applicable

# E Expected Values/Reference Range:

In the clinical study, a total of 1107 left-over, de-identified, unpreserved liquid or soft stool specimens sequentially collected from patients suspected of $C .$ . difficile infection were enrolled from three geographically diverse sites in the US. Of these specimens, 1046 provided valid test results for analysis of which 96 were positive by the cellular cytotoxicity neutralization assay comparator for an overall observed prevalence of $9 . 2 \%$ (96/1046). The overall percentage of positive results observed with the SensiTox $C .$ . difficile Toxin Test was $1 2 . 2 \%$ (128/1046).

# F Other Supportive Instrument Performance Characteristics Data:

Not applicable

# VIII Proposed Labeling:

The labeling supports the finding of substantial equivalence for this device.

# IX Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.